Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral semaglutide monotherapy delivers HbA1c improvements in type 2 diabetes

Publish date:: August 12, 2019

Key clinical point: Oral semaglutide monotherapy significantly reduced HbA_1c in patients with type 2 diabetes, compared with placebo in patients managed by diet and exercise alone.

Major finding: At 26 weeks, the differences in HbA_1c for medication daily doses of 3 mg, 7 mg, and 14 mg using an intention-to-treat analysis, were –0.6%, –0.9%, and –1.1%, respectively (P less than .001 for all).

Study details: A randomized, double-blind, placebo-controlled, multicenter trial of 703 adults with type 2 diabetes.

Disclosures: Novo Nordisk funded the study. The lead author disclosed relationships with Novo Nordisk, and several coauthors disclosed relationships with or employment by the company.

Citation:

Aroda VR et al. Diabetes Care. 2019 Jul. doi: 10.2337/dc19-0749.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,